Nivolumab and cabozantinib versus standard of care in renal cell carcinoma

Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the results of clinical trials reported at the European Cancer Congress (ECC) 2015 in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus.

Year of Production:
Running Time:
Color/Sound:

2015
03:25
Color/Sound

Comments are closed.